Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Arcellx Inc.

Changes in Beneficial Ownership

Filed Apr 28, 2026Accepted Apr 28, 2026, 4:28 PM EDTFiling CIK 1786205Accession 0001572000-26-000002
Share

Structured filing — 4

form4-04282026_080414.xml

Open full document ↗

Filing details

Report period
2026-04-28
Issuer
Arcellx, Inc.
Issuer CIK
0001786205
Trading symbol
ACLX
No longer subject to Section 16
Checked

Reporting owner 1

Name
Lubner David Charles
Reporting owner CIK
0001572000
Relationship
Director
Address
C/O ARCELLX, INC., 800 BRIDGE PARKWAY, REDWOOD CITY, CA, 94065

Non-derivative transactions

Non-derivative transactions · 1 reported row
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
Common Stock2026-04-28U · Form 421,659D[F1]0D
Table key
U · Form 4
Shares tendered in a change of control
D
Direct

Derivative transactions

Derivative transactions · 7 reported rows
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Stock Option (right to buy)6.832026-04-28D · Form 413,626D[F2][F2]2030-08-31Common Stock13,6260D
Stock Option (right to buy)6.282026-04-28D · Form 459,405D[F2][F2]2031-06-09Common Stock59,4050D
Stock Option (right to buy)6.662026-04-28D · Form 431,794D[F2][F2]2031-12-07Common Stock31,7940D
Stock Option (right to buy)152026-04-28D · Form 461,538D[F2][F2]2032-02-03Common Stock61,5380D
Stock Option (right to buy)37.942026-04-28D · Form 411,459D[F2][F2]2033-06-14Common Stock11,4590D
Stock Option (right to buy)51.302026-04-28D · Form 48,011D[F2][F2]2034-05-28Common Stock8,0110D
Stock Option (right to buy)63.682026-04-28D · Form 49,174D[F2][F2]2035-05-29Common Stock9,1740D
Table key
D · Form 4
Disposition to the issuer under Rule 16b-3(e)
D
Direct

Footnotes

F1
Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share ("Closing Amount"), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a "CVR"), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.↩ 1
F2
Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9↩ 10↩ 11↩ 12↩ 13↩ 14

Signature 1

Signed
/s/ Michelle Gilson, as Attorney-in-Fact
Date
2026-04-28

Company context

Historical securities (1)

Recent company filings

  1. SCHEDULE 13G/A - filed by Vestal Point Capital, LP regarding Arcellx, Inc.May 15, 2026
  2. 15-12G filingMay 8, 2026
  3. 4 filingApr 28, 2026
  4. 4 filingApr 28, 2026
  5. 4 filingApr 28, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.